ClinicalTrials.gg
RecruitingNCT05982119Updated May 20, 2025

Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study

An interventional study of ActiMyo/Syde in Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy and Myotonic Dystrophy 1, sponsored by Centre Hospitalier Universitaire de Liege. Recruiting at 8 sites in 7 countries. Open to participants aged 1 Year to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Jul 2020, registered Jul 2021).
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
1 Year to 80 Years
Sex
All
01

Study summary

The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.

02

Conditions studied

  • Duchenne Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy
  • Myotonic Dystrophy 1
  • Charcot-Marie-Tooth
  • Centronuclear Myopathy
  • Congenital Muscular Dystrophy
03

In context

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

This study's planned enrollment of 300 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.

Browse Muscular Dystrophy, Duchenne studies →

Lead sponsor

Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For the patients:

    • Genetically confirmed diagnosis of DMD, FSHD, DM1, CMT or FKRP mutations or confirmed CNM based on muscle .
    • FSHD, DM1, CMT and CNM patients should be ambulant or in transition.
    • DM1 and CMT patients should present sensori-motor signs on physical examination.
    • Under the age of 20 years for patients with DMD, CNM or between the ages of 5 and 80 years for patients with FSHD, CMT and DM1.
    • More than 2 years old for patients with FKRP mutations
    • Non-ambulant DMD patients must be able to remain seated in an arm- or a wheelchair for at least one hour.
    • Patients with DMD treated with for at least 6 months or initiated corticosteroid at V0 (except for patients under 4).
    • Signed form by patient himself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians.
  • For the control subjects:

    • Ambulant boys and girls under 20 years old
    • Signed informed consent form by patient him/herself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians.

Exclusion criteria

Exclusion Criteria:

  • For the patients:

    • Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed.
    • Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs (for ambulant patients).
    • A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion.
    • Patients who are participating in an interventional clinical trial.
    • DMD patients in transition who are not on .
  • For the control subjects:

    • Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs.
    • Elite athletes (at the national level).
    • A chronic or acute muscular, neurological, infectious, or inflammatory pathology within the 3-week period immediately prior to inclusion.
    • An orthopedic, neuromuscular, or neurological pathology that affects the quality of the subject's walking gait.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    Patients with DMD/FSHD/CMT/DM1/CNM/FKRPmutation or control subjects

    Patients and control subjects will be included over a 3-years study period. Patients will be examined by a neuropaediatrician or neurologist and perform standardized assessments (timed tests, motor function tests, and strength tests) at baseline and then every 6 to 12 months (depending on age). From February 2024, controls subjects can be remotely recruited and enrolled. They won't be evaluated on site, but data, such as age, sex, weight, and height, will be collected by phone or visio-conference at inclusion and every 6 months for 3 years. Patients will be asked to wear the device during 1 to 3 months at baseline (depending on disease group) and then for 1 month every 3-12months (depending on age and disease group). Control subjects will be examined by a physician and perform the same tests than those for ambulant patients at baseline and 12 months. Control subjects will be asked to wear the device for two months (one month at inclusion, one month 11 months after inclusion).

    Device: ActiMyo/Syde

Interventions

  • DeviceActiMyo/Syde

    The two "watches" can be worn as wristwatch or placed near the ankle and on the wheelchair. * Patients with DMD or FKRP mutation will wear the ActiMyo°/Syde° during 3 months at baseline and then for one month every 3 months. * Patient with FSHD, DM1, CMT, CNM will wear the ActiMyo°/Syde° will wear the ActiMyo/Syde° during 3 months at baseline and then for one month every 6 months. * Control subjects \>4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month 11 months after inclusion. * Control subjects \<4years will wear the ActiMyo°/Syde° during one month after inclusion and during one other month every 6months after inclusion.

06

What researchers measure

Primary outcomes

  1. Stride velocity

    Stride velocity obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter per second).

    Time frame: through study completion (3 year)

  2. Stride length

    Stride length obtained with a magneto-inertial sensor (Actimyo°) in real-life (meter).

    Time frame: through study completion (3 year)

  3. Stairs number

    Total number of strides in stairs obtained with a magneto-inertial sensor (Actimyo°) in real-life

    Time frame: through study completion (3 year)

  4. Stairs speed

    Vertical speed during strides in stairs obtained with a magneto-inertial sensor (Actimyo°) in real-life

    Time frame: through study completion (3 year)

  5. Stairs height

    Height of the strides in stairs obtained with a magneto-inertial sensor (Actimyo°) in real-life

    Time frame: through study completion (3 year)

07

Study locations

2 of 8 sites recruiting
  • CHR de la Citadelle
    Liège, 4000, Belgium
    Recruiting
  • Fakultni nemocnice v Motole
    Prague, Czechia
    Active, not recruiting

    Not enrolling at this site.

  • Galaa Military Medical Complex
    Cairo, Egypt
    Active, not recruiting

    Not enrolling at this site.

  • Semmelweis University 2nd Department of Paediatrics
    Budapest, Hungary
    Active, not recruiting

    Not enrolling at this site.

  • Warsaw Medical University Hospital, Department of Neurology
    Warsaw, Poland
    Active, not recruiting

    Not enrolling at this site.

  • National Clinical Hospital for Children Neurohabilitation "Dr Nicolae Robanescu"
    Bucarest, Romania
    Active, not recruiting

    Not enrolling at this site.

  • Pediatric Neurology Clinic, Clinical Hospital of Psychiatry "Prof. Dr. Al. Obregia"
    Bucharest, 041914, Romania
    Recruiting
  • University Children's Hospital, Department for Pediatric Neurology
    Ljubljana, Slovenia
    Active, not recruiting

    Not enrolling at this site.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Mar 2026, 68 months after the start.

Of 45 non-industry interventional studies with no phase under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 68 months is above that.

Counting every sponsor, half of 47 studies reached it within 20 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Aug 8, 2023
StartActual
Jul 10, 2020
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05982119
Lead sponsor
Centre Hospitalier Universitaire de Liege
Collaborators
SYSNAV
Responsible party
Laurent Servais (Professor Laurent Servais, Centre Hospitalier Universitaire de Liege) — Principal investigator
First posted
Aug 8, 2023
Start date
Jul 10, 2020
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
May 20, 2025

Study contacts

Charline DUBOIS
Contact
charline.dubois@citadelle.be
043215695 ext. +32

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion